ISABEL MANUELA
ÁLVAREZ LÓPEZ
Hospital Clínico San Carlos de Madrid
Madrid, EspañaPublications en collaboration avec des chercheurs de Hospital Clínico San Carlos de Madrid (7)
2022
-
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
Breast, Vol. 66, pp. 77-84
-
Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment
Journal of Clinical Investigation, Vol. 132, Núm. 7
2021
-
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL
Annals of Oncology, Vol. 32, Núm. 4, pp. 488-499
-
The pseudokinase TRIB3 negatively regulates the HER2 receptor pathway and is a biomarker of good prognosis in luminal breast cancer
Cancers, Vol. 13, Núm. 21
2010
-
Current controversies in the management of breast cancer
Clinical and Translational Oncology, Vol. 12, Núm. 4, pp. 278-286
-
Erratum: Current controversies in the management of breast cancer (Clinical and Translational Oncology 12:4 (278-286))
Clinical and Translational Oncology
2008
-
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer
Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814